Biotech3 months ago
Oryzon up 3% After Progress in Trial of Its Drug for Personality Disorder
Oryzon Genomics shares rose 2.8% after receiving positive FDA feedback on vafidemstat for borderline personality disorder. The company plans a Phase III study with 350 patients...